$145.19
-2.18
(-1.48%)
As of Oct 15, 2026, 9:48 PM EDT
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Jul 29, 2026, the first target we tracked for MRK.
Merck & Co. (MRK) is trading down at $145.19 (-1.48%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on MRK
Current price targets from 11 firms average $166, median $170, ranging from $145 to $180 — the average is 14% above the current $145. Each is tracked to its date and scored the same way a member's call is.
- RBC Capital Markets $145 → $145 by Oct 2027 Oct 12, 2026 via MarketBeat · RBC Capital Markets's track record
- Cantor Fitzgerald $142 → $145 by Oct 2027 Oct 8, 2026 via MarketBeat · Cantor Fitzgerald's track record
- Morgan Stanley $143 → $177 by Oct 2027 Oct 7, 2026 via MarketBeat · Morgan Stanley's track record
- JPMorgan $140 → $165 by Oct 2027 Oct 5, 2026 via MarketBeat · JPMorgan's track record
- Scotiabank $149 → $180 by Sep 2027 Sep 29, 2026 via marketbeat.com · Scotiabank's track record
- HSBC $145 → $172 by Sep 2027 Sep 10, 2026 via GuruFocus · HSBC's track record
- Guggenheim $148 → $170 by Sep 2027 Sep 8, 2026 via GuruFocus · Guggenheim's track record
- Wolfe Research $156 → $180 by Aug 2027 Aug 25, 2026 via GuruFocus · Wolfe Research's track record
- Argus Research $156 → $170 by Aug 2027 Aug 25, 2026 via GuruFocus · Argus Research's track record
- BMO Capital Markets $149 → $170 by Aug 2027 Aug 20, 2026 via GuruFocus · BMO Capital Markets's track record
- RBC Capital Markets $149 → $150 by Aug 2027 Aug 20, 2026 via GuruFocus · RBC Capital Markets's track record
- Morgan Stanley $149 → $179 by Aug 2027 Aug 20, 2026 via GuruFocus · Morgan Stanley's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Merck & Co. revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $39.8B | $40.1B | $42.3B | $39.1B | $41.5B | $48.7B | $59.3B | $60.1B | $64.2B | $65.0B |
| Growth (year over year) | +0.8% | +0.8% | +5.4% | −7.5% | +6.1% | +17.3% | +21.7% | +1.4% | +6.7% | +1.3% |
| Gross profit | $25.8B | $27.2B | $28.8B | $27.1B | $27.9B | $35.1B | $41.9B | $44.0B | $49.0B | $48.6B |
| Gross margin | 64.8% | 67.8% | 68.1% | 69.3% | 67.2% | 72.0% | 70.6% | 73.2% | 76.3% | 74.8% |
| Net income | $3.92B | $2.39B | $6.22B | $9.84B | $7.07B | $13.0B | $14.5B | $365.0M | $17.1B | $18.3B |
| Net margin | 9.8% | 6.0% | 14.7% | 25.2% | 17.0% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% |
| EPS (diluted) | $1.41 | $0.87 | $2.32 | $3.81 | $2.78 | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 |
| Balance sheet | ||||||||||
| Cash and equivalents | $6.51B | $6.09B | $7.96B | $9.68B | $8.05B | $8.10B | $12.7B | $6.84B | $13.2B | $14.6B |
| Total assets | $95.4B | $87.9B | $82.6B | $84.4B | $91.6B | $105.7B | $109.2B | $106.7B | $117.1B | $136.9B |
| Total liabilities | $55.1B | $53.3B | $55.8B | $58.4B | $66.2B | $67.4B | $63.1B | $69.0B | $70.7B | $84.2B |
| Long-term debt | $24.3B | $21.4B | $19.8B | $22.7B | $25.4B | $30.7B | $28.7B | $33.7B | $34.5B | $46.8B |
| Shareholders' equity | $40.1B | $34.3B | $26.7B | $25.9B | $25.3B | $38.2B | $46.0B | $37.6B | $46.3B | $52.6B |
| Cash flow | ||||||||||
| Operating cash flow | $10.4B | $6.45B | $10.9B | $13.4B | $10.3B | $13.1B | $19.1B | $13.0B | $21.5B | $16.5B |
| Capital expenditure | $1.61B | $1.89B | $2.62B | $3.37B | $4.43B | $4.45B | $4.39B | $3.86B | $3.37B | $4.11B |
| Free cash flow | $8.76B | $4.56B | $8.31B | $10.1B | $5.82B | $8.67B | $14.7B | $9.14B | $18.1B | $12.4B |
| Dividends paid | $5.12B | $5.17B | $5.17B | $5.70B | $6.21B | $6.61B | $7.01B | $7.45B | $7.84B | $8.18B |
| Share buybacks | $3.43B | $4.01B | $9.09B | $4.78B | $1.28B | $840.0M | $0 | $1.35B | $1.31B | $5.08B |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $16.7B | $15.6B | $15.5B | $15.8B | $17.3B | $16.4B | $16.3B | $16.6B |
| Growth (year over year) | +4.4% | +6.8% | −1.6% | −1.9% | +3.7% | +5.0% | +4.9% | +5.1% |
| Gross profit | $12.6B | $11.8B | $12.1B | $12.2B | $13.4B | $10.8B | $12.1B | $12.2B |
| Gross margin | 75.5% | 75.5% | 78.0% | 77.5% | 77.7% | 66.2% | 74.2% | 73.5% |
| Net income | $3.16B | $3.74B | $5.08B | $4.43B | $5.79B | $2.96B | −$4.24B | −$1.33B |
| Net margin | 19.0% | 24.0% | 32.7% | 28.0% | 33.5% | 18.1% | −26.0% | −8.0% |
| EPS (diluted) | $1.24 | $1.49 | $2.01 | $1.76 | $2.32 | $1.19 | −$1.72 | −$0.54 |
| Balance sheet | ||||||||
| Cash and equivalents | $14.6B | $13.2B | $8.63B | $8.01B | $18.2B | $14.6B | $5.33B | $6.85B |
| Total assets | $117.5B | $117.1B | $115.1B | $117.5B | $129.5B | $136.9B | $128.7B | $129.8B |
| Total liabilities | $73.0B | $70.7B | $66.7B | $68.5B | $77.6B | $84.2B | $82.8B | $87.8B |
| Long-term debt | $35.0B | $34.5B | $33.5B | $34.0B | $40.0B | $46.8B | $46.7B | $51.1B |
| Shareholders' equity | $44.5B | $46.3B | $48.3B | $49.0B | $51.9B | $52.6B | $45.9B | $41.9B |
| Cash flow | ||||||||
| Operating cash flow | $9.29B | $3.45B | $2.50B | $3.29B | $7.82B | $2.86B | $3.92B | $5.37B |
| Capital expenditure | $783.0M | $937.0M | $1.33B | $764.0M | $987.0M | $1.03B | $991.0M | $893.0M |
| Free cash flow | $8.51B | $2.51B | $1.17B | $2.53B | $6.83B | $1.82B | $2.93B | $4.48B |
| Dividends paid | $1.95B | $1.95B | $2.05B | $2.08B | $2.03B | $2.02B | $2.10B | $2.14B |
| Share buybacks | $444.0M | $489.0M | $1.16B | $1.34B | $1.32B | $1.25B | $874.0M | $757.0M |
From Merck & Co.'s 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Merck & Co.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
Source: Wikipedia — Merck & Co.
- Headquarters
- Rahway, New Jersey From SEC filings, Oct 2026
Recent News (20)
-
Merck (MRK) Adds A Board Veteran, Is It Still 5% Below Fair Value? Merck (MRK) Adds A Board Veteran, Is It Still 5% Below Fair Value? Simply Wall Street
-
Curated Wealth Partners LLC Sells 127,541 Shares of Merck & Co., Inc. $MRK Curated Wealth Partners LLC Sells 127,541 Shares of Merck & Co., Inc. $MRK MarketBeat
-
AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow Yahoo Finance
-
Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine Yahoo Finance
-
-
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock Yahoo Finance
-
-
-
-
-
-
-
-
MRK Stock Gains 3.80% on Wednesday: What to Know MRK Stock Gains 3.80% on Wednesday: What to Know JournalArta
-
-
-
-
-
-
More Health Care stocks
- LH Labcorp
- LLY Lilly (Eli)
- MCK McKesson Corporation
- MDT Medtronic
- MRNA Moderna
- MTD Mettler Toledo
- PFE Pfizer
- PODD Insulet Corporation